These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 32604776)

  • 1. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
    Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Discovery Perspectives of Antisense Oligonucleotides.
    Kim Y
    Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides: a novel Frontier in pharmacological strategy.
    Collotta D; Bertocchi I; Chiapello E; Collino M
    Front Pharmacol; 2023; 14():1304342. PubMed ID: 38044945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
    Nakamura A; Ali SA; Kapoor M
    Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
    Rinaldi C; Wood MJA
    Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of marketed antisense oligonucleotide drugs.
    Wu H; Wahane A; Alhamadani F; Zhang K; Parikh R; Lee S; McCabe EM; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Curr Opin Toxicol; 2022 Dec; 32():. PubMed ID: 37193356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
    Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides: a promising therapeutic option against infectious diseases.
    Tekintaş Y; Temel A
    Nucleosides Nucleotides Nucleic Acids; 2024; 43(1):1-39. PubMed ID: 37395450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.
    Gagliardi M; Ashizawa AT
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33923688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC Organoids.
    Wan L; Kral AJ; Voss D; Krainer AR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic antisense oligonucleotides for movement disorders.
    Doxakis E
    Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
    Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
    Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.